# A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy

> **NCT02767765** · PHASE3 · COMPLETED · sponsor: **Hoffmann-La Roche** · enrollment: 61 (actual)

## Conditions studied

- Anemia

## Interventions

- **DRUG:** r-HuEPO

## Key facts

- **NCT ID:** NCT02767765
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2006-10
- **Final completion:** 2006-10
- **Target enrollment:** 61 (ACTUAL)
- **Last updated:** 2017-04-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02767765

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02767765, "A Study of Recombinant Human Erythropoietin Beta (NeoRecormon) in Anemic Cancer Participants Treated With Chemotherapy". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT02767765. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*